Please login to the form below

Not currently logged in


This page shows the latest pomalidomide news and features for those working in and with pharma, biotech and healthcare.

Sanofi's Darzalex rival scores in myeloma trial

Sanofi's Darzalex rival scores in myeloma trial

s Pomalyst/Imnovid (pomalidomide) and low-dose dexamethasone. ... According to Sanofi, this is the first time that an antibody drug has been shown a benefit when added to pomalidomide and dexamethasone for treatment of relapsed/refractory myeloma.

Latest news

More from news
Approximately 6 fully matching, plus 21 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...